Ðǿմ«Ã½

    Advertisement

    We only need a few more clicks to be able to show the most read stories for this topic. Take a look at the latest headlines below and help us out by clicking on what you find interesting!

    In the last 4 hours
    LabOnline10:35
    Earlier today
    ecancer00:12
    Yesterday
    Business Wire (Press Release)23:09 7-May-26
    News-Medical.Net11:36 7-May-26
    Nature.com01:27 7-May-26
    Nature.com01:27 7-May-26
    Nature.com01:03 7-May-26
    Nature.com01:03 7-May-26
    Newswise (Press Release)01:02 7-May-26
    In the last 7 days
    Simply Wall St20:07 6-May-26
    Labiotech19:23 6-May-26
    News-Medical.Net12:33 6-May-26
    Barchart04:10 6-May-26
    Penn State News01:43 6-May-26
    Rare Disease Advisor01:07 6-May-26
    Pharmaceutical Technology00:57 6-May-26
    Zacks23:27 5-May-26
    Scientific American21:55 5-May-26
    Business Wire (Press Release)21:01 5-May-26
    Zacks10:33 5-May-26
    Drug Discovery & Development07:31 5-May-26
    Rare Disease Advisor05:04 5-May-26
    Rare Disease Advisor04:44 5-May-26
    Rare Disease Advisor02:22 5-May-26
    UQ News00:19 5-May-26
    Gulf News09:19 4-May-26
    Vox21:54 2-May-26
    The Scientist14:10 2-May-26
    PR Newswire (Press Release)06:02 2-May-26
    American College of Cardiology22:03 1-May-26
    News-Medical.Net04:46 1-May-26
    Newswise (Press Release)01:59 1-May-26
    Reason01:43 1-May-26
    In the last month
    PR Newswire (Press Release)22:31 30-Apr-26
    Business Wire (Press Release)22:08 30-Apr-26
    Business Wire (Press Release)21:05 30-Apr-26
    Reason20:17 30-Apr-26
    University of Bonn20:14 30-Apr-26
    The Motley Fool19:20 30-Apr-26
    Labiotech18:03 30-Apr-26
    The Motley Fool01:31 30-Apr-26
    Nature.com01:22 30-Apr-26
    Nature.com01:06 30-Apr-26
    Nature.com01:06 30-Apr-26
    The Cardiology Advisor23:38 29-Apr-26
    Business Wire (Press Release)22:01 29-Apr-26
    Business Wire (Press Release)21:03 29-Apr-26
    Pharmaceutical Technology21:02 29-Apr-26
    South Wales Argus14:12 29-Apr-26
    Simply Wall St12:00 29-Apr-26
    Nature.com11:30 29-Apr-26
    Hoodline09:45 29-Apr-26
    Zacks09:02 29-Apr-26
    Scrip Pharma Intelligence07:08 29-Apr-26
    Benzinga05:08 29-Apr-26
    Zacks04:07 29-Apr-26
    JD Supra04:04 29-Apr-26
    pharmaphorum22:36 28-Apr-26
    Business Wire (Press Release)21:02 28-Apr-26
    IFLScience20:33 28-Apr-26
    Farming UK18:27 28-Apr-26
    Nature.com17:03 28-Apr-26
    RTT News11:15 28-Apr-26
    Bloomberg Law07:12 28-Apr-26
    Barchart04:49 28-Apr-26
    Investing.com UK03:03 28-Apr-26
    Clinical Trials Arena02:14 28-Apr-26
    BioPharma Dive00:17 28-Apr-26
    JD Supra00:07 28-Apr-26
    pharmaphorum23:41 27-Apr-26
    STAT23:29 27-Apr-26
    Zacks23:10 27-Apr-26
    STAT21:05 27-Apr-26
    News-Medical.Net03:10 27-Apr-26
    Nature.com23:02 25-Apr-26
    RTT News21:08 25-Apr-26
    NOEMA03:04 25-Apr-26
    ZME Science00:01 25-Apr-26
    Simply Wall St00:01 25-Apr-26
    Labiotech23:02 24-Apr-26
    view more headlines
    8 May 10:35

    About our CRISPR/Gene Editing news

    Latest news on CRISPR/Gene Editing, covering breakthroughs, applications, ethics, regulations, and implications for health, agriculture, and biotechnology. Stay informed on this revolutionary technology.

    CRISPR/Cas9, the groundbreaking gene-editing tool, has revolutionised the field of genetics and biotechnology since its discovery in 2012. Developed by scientists Jennifer Doudna and Emmanuelle Charpentier, who were awarded the Nobel Prize in Chemistry in 2020, CRISPR allows for precise, efficient, and cost-effective editing of DNA sequences in living organisms.

    The potential applications of CRISPR are vast, spanning healthcare, agriculture, and beyond. In medicine, CRISPR holds promise for treating genetic disorders, developing novel therapies for diseases like cancer and HIV, and even potentially enhancing human traits. Recent breakthroughs include the first clinical trials of CRISPR-based treatments for sickle cell anemia and beta-thalassemia, as well as advancements in using CRISPR to target antibiotic-resistant bacteria.

    In agriculture, CRISPR is being explored to develop more resilient, nutritious, and sustainable crops, as well as to create disease-resistant livestock. Companies like Corteva Agriscience and Calyxt are at the forefront of these efforts. However, the use of CRISPR in agriculture has also sparked debates about GMO regulations, labelling, and public acceptance.

    Despite its immense potential, CRISPR also raises significant ethical and societal concerns. The prospect of human germline editing, which could alter the genetic makeup of future generations, has been particularly controversial. In 2018, Chinese scientist He Jiankui claimed to have created the world's first gene-edited babies, sparking global outcry and calls for stricter oversight. Organizations like the World Health Organization and the National Academies of Sciences have issued guidelines and recommendations for the responsible development and governance of gene editing.

    Stay up-to-date on the latest CRISPR/Gene Editing news with our dedicated feed, covering everything from cutting-edge research and clinical trials to policy developments and societal debates, as this transformative technology continues to shape our future.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.